Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2002
12/27/2002WO2002102817A1 Anti-tumour anthracycline glycoside 14-sulfonic acid derivatives
12/27/2002WO2002102808A2 (PYRIDO/THIENO)-[f]-OXAZEPIN-5-ONE DERIVATIVES AS POSITIVE MODULATORS OF THE AMPA RECEPTOR
12/27/2002WO2002102807A1 Novel isoxazolopyridone derivatives and use thereof
12/27/2002WO2002102805A1 NEW USE Of CYCLOLIGNANS AND NEW CYCLOLIGNANS
12/27/2002WO2002102804A1 New use of specific cyclolignans
12/27/2002WO2002102800A1 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
12/27/2002WO2002102799A2 Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists
12/27/2002WO2002102792A1 Novel heterocyclic antibacterial compounds
12/27/2002WO2002102791A1 Pyrrolidine bicyclic compounds
12/27/2002WO2002102790A1 N-formyl hydroxylamine compounds as inhibitors of pdf
12/27/2002WO2002102787A2 Novel sulfonic acid derivatives
12/27/2002WO2002102782A2 QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE
12/27/2002WO2002102780A1 Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient
12/27/2002WO2002102778A1 Phenylpyridine carbonyl piperazine derivative
12/27/2002WO2002102777A2 NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERINDINYL]-1-HYDROXYBUTYL]-α, α-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE
12/27/2002WO2002102776A1 Process for the production of the piperidine derivative fexofenadine
12/27/2002WO2002102774A1 4-piperazinylindole derivatives with 5-ht6 receptor affinity
12/27/2002WO2002102771A1 Tryptase inhibitors
12/27/2002WO2002102768A2 Regulation of neuronal function through metabotropic glutamate receptor signaling pathways
12/27/2002WO2002102766A2 Combretastatin a-3 prodrug
12/27/2002WO2002102445A1 Dry powder inhalation system for transpulmonary administration
12/27/2002WO2002102414A1 Medicinal compositions
12/27/2002WO2002102403A1 Mucosal repair by tff dimer peptides
12/27/2002WO2002102402A1 Anticancer agents
12/27/2002WO2002102399A2 Mucosal repair by tff2 peptides
12/27/2002WO2002102391A2 Composition comprising nanoparticulate spironolactone
12/27/2002WO2002102390A1 Enhanced drug delivery in transdermal systems
12/27/2002WO2002102389A1 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
12/27/2002WO2002102388A2 Active ingredient combination of e.g. galanthamine or deoxypeganine and e.g. acamprosate or memantine for treating an addiction such as alcoholism
12/27/2002WO2002102386A1 Methods and pharmaceuticals for treating muscle insulin resistance and related conditions
12/27/2002WO2002102383A1 Aqueous cilostazol preparation for injection
12/27/2002WO2002102382A1 A PROCESS FOR PREPARING PAROXETINE HCl WHICH LIMITS FORMATION OF PINK COLORED COMPOUNDS
12/27/2002WO2002102381A1 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage
12/27/2002WO2002102380A1 Monocyclic or bicyclic carbocycles and heterocycles as factor xa inhibitors
12/27/2002WO2002102376A1 ORALLY DELIVERABLE PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE COMPOUND HAVING AN AMINOSULFONYL GROUP (cox-2 INHIBITOR), A POLYETHYLENE GLYCOL AND A FREE-RADICAL SCAVENGING ANTIOXIDANT
12/27/2002WO2002102361A1 Remedies for diseases caused by nonsense mutation
12/27/2002WO2002102359A2 Alkylidene pyrazolidinedione derivatives and use for treating diabetes and obesity
12/27/2002WO2002102357A1 A coated nicotine-containing chewing gum, manufacture and use thereof
12/27/2002WO2002102346A1 Use of at least one 10-hydroxy-2-decenoic acid derivative in compositions for treating the cutaneous signs of ageing
12/27/2002WO2002102344A2 No-synthase inhibitor and use thereof
12/27/2002WO2002102343A1 Ascorbyl 2-hexadecanoate as a no-synthase inhibitor
12/27/2002WO2002102340A2 Use of carnitine and/or one or more acyl-carnitines for producing cosmetic or dermatological preparations
12/27/2002WO2002102320A2 Fce fusion proteins for treatment of allergy and asthma
12/27/2002WO2002102315A2 QUINAZOLINE AND PYRIDO[2,3-d]PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7
12/27/2002WO2002102314A2 Purine inhibitors of phosphodiesterase (pde) 7
12/27/2002WO2002102313A2 Pyrimidine inhibitors of phosphodiesterase (pde) 7
12/27/2002WO2002102312A2 Combination therapy of gamma-interferon and b cell specific antibodies
12/27/2002WO2002102306A2 Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
12/27/2002WO2002102297A2 Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders
12/27/2002WO2002102229A2 Diagnosing tumorigenicity and determining resistance to anticancer therapy
12/27/2002WO2002102144A1 Cell deah-inducible model nonhuman animal
12/27/2002WO2002087626A9 Pharmaceutical compositions comprising dendritic cells for immunotherapy of autoimmune disease and treatment methods using the same
12/27/2002WO2002072077A3 Use of amino acids, amino acid analogues, sugar phosphates and sugar phosphate analogues for treatment of tumors, treatment of sepsis and immunosuppression
12/27/2002WO2002070473A3 Carboxamide derivatives as therapeutic agents
12/27/2002WO2002069989A3 Aquatic animal treatment method and composition containing pimenta extract
12/27/2002WO2002062335A3 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
12/27/2002WO2002060922A3 Epoxyvibsanin b
12/27/2002WO2002057415A3 Method for altering cell fate
12/27/2002WO2002056874A3 Lipid-based nitric oxide donors
12/27/2002WO2002055099A3 Modulation of pericyte proliferation using bpi protein products or bpi inhibitors
12/27/2002WO2002053142A3 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
12/27/2002WO2002051994A3 Polypeptides
12/27/2002WO2002049593A3 Use of dna repair enzymes as mmp-1 inhibitors
12/27/2002WO2002046181A3 Abca-1 elevating compounds against coronary artery disease or atherosclerosis
12/27/2002WO2002018445A8 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
12/27/2002WO2002012467A3 Drug metabolizing enzymes
12/27/2002WO2002010379B1 Modified cea and uses thereof
12/27/2002WO2002004623A3 ANTISENSE COMPOSITIONS TARGETED TO β1 ADRENOCEPTOR-SPECIFIC MRNA AND METHODS OF USE
12/27/2002WO2001097829A3 Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
12/27/2002WO2001087935A9 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)
12/27/2002WO2001085937A3 Regulator of g protein signalling (rgs8)
12/27/2002WO2001064956A3 The identification and use of effectors and allosteric molecules for the alteration of gene expression
12/27/2002WO2001052855A8 Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
12/27/2002CA2646802A1 Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-.alpha.,.alpha.-dimethylbenzene acetic acid and its hydrochloride
12/27/2002CA2455387A1 Fce fusion proteins for treatment of allergy and asthma
12/27/2002CA2451057A1 Novel isoxazolopyridone derivatives and use thereof
12/27/2002CA2450936A1 Purine inhibitors of phosphodiesterase (pde) 7
12/27/2002CA2450934A1 Pyrimidine inhibitors of phosphodiesterase (pde) 7
12/27/2002CA2450809A1 Methods for detecting and treating the early onset of aging-related conditions
12/27/2002CA2450730A1 Methods for sterilizing preparations of monoclonal immunoglobulins
12/27/2002CA2450724A1 Quinazoline and pyrido¬2,3-d|pyrimidine inhibitors of phosphodiesterase (pde) 7
12/27/2002CA2450700A1 Trx1 antibody and uses therefor
12/27/2002CA2450666A1 Diagnosing tumorigenicity and determining resistance to anticancer therapy
12/27/2002CA2450659A1 Tryptase inhibitors
12/27/2002CA2450590A1 Methods and compositions for inhibiting, preventing or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
12/27/2002CA2450245A1 4-piperazinylindole derivatives with 5-ht6 receptor affinity
12/27/2002CA2450074A1 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage
12/27/2002CA2449977A1 Human growth hormone antagonists
12/27/2002CA2449950A1 Agents for treating diseases caused by nonsense mutation
12/27/2002CA2449909A1 Male contraceptives
12/27/2002CA2449212A1 Alkylidene pyrazolidinedione derivatives and use for treating diabetes and obesity
12/27/2002CA2448526A1 N-formyl hydroxylamine compounds as inhibitors of pdf
12/27/2002CA2448298A1 Phenylpyridine carbonyl piperazine derivative
12/27/2002CA2447808A1 A process for preparing paroxetine hci which limits formation of pink colored compounds
12/27/2002CA2447624A1 Anti-tumour compound
12/27/2002CA2446931A1 Pyrrolidine bicyclic compounds
12/27/2002CA2446284A1 Method for identification of agents for the treatment of diabetes
12/27/2002CA2444356A1 Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (cox-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant
12/27/2002CA2443466A1 An aqueous pharmaceutical preparation of cilostazol for parenteral use
12/27/2002CA2429113A1 Monocyclic or bicyclic carbocycles and heterocycles as factor xa inhibitors
1 ... 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 ... 1564